Eisai Revises Leqembi Sales Forecast for 2027, Remains Optimistic About Growth
Eisai has lowered its sales forecast for Leqembi in fiscal year 2027 to 250-280 billion yen ($1.6-1.8 billion)25.
This revised projection is approximately half of the previous forecast of 290 billion yen for fiscal year 202610.
Despite the reduction, Eisai considers the 2027 forecast a "significant milestone" towards its long-term sales target10.
Leqembi's current fiscal year 2024 revenue target remains at 42.5 billion yen ($279 million)56.
The drug's uptake has been slower than initially anticipated, particularly in the U.S. market46.
Eisai is pursuing strategies to boost Leqembi's adoption, including developing a subcutaneous formulation and expanding brand awareness56.
The company maintains its long-term sales goal of 1.3 trillion yen ($8.6 billion) for Leqembi by fiscal year 20325.
Leqembi has received approvals in multiple countries, including the U.S., Japan, China, and South Korea11.
Eisai and its partner Biogen are facing competition from other Alzheimer's treatments, such as Eli Lilly's donanemab6.
The company remains confident in Leqembi's potential, citing "continued growth" and expanding patient access56.
Sources:
2. https://www.stocktitan.net/news/B/bio-arctic-s-partner-eisai-presents-sales-simulation-for-leqembi-at-fodnh73085dz.html
4. https://endpts.com/eisai-slashes-leqembi-sales-forecast-by-almost-100m/
5. https://www.fiercepharma.com/pharma/eisai-lays-out-road-map-blockbuster-sales-projections-leqembis-milestone-2027-year
6. https://www.biospace.com/business/as-us-sales-of-leqembi-lag-eisai-eyes-subq-approvals